Deferred Tax Assets, Net of Valuation Allowance of PharmaCyte Biotech, Inc. from 30 Apr 2012 to 30 Apr 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
PharmaCyte Biotech, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 30 Apr 2012 to 30 Apr 2025.
  • PharmaCyte Biotech, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 30 Apr 2025 was $15,221,718, a 0.18% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

PharmaCyte Biotech, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $15,221,718 +$27,998 +0.18% 30 Apr 2025 10-K 11 Aug 2025 2025 FY
Q1 2024 $15,193,720 +$15,193,720 30 Apr 2024 10-K 11 Aug 2025 2025 FY
Q1 2023 $0 $0 30 Apr 2023 10-K 13 Aug 2024 2024 FY
Q1 2022 $0 $0 30 Apr 2022 10-K 31 Jul 2023 2023 FY
Q1 2021 $0 $0 30 Apr 2021 10-K 28 Jul 2022 2022 FY
Q1 2020 $0 -$14,187,771 -100% 30 Apr 2020 10-K 10 Aug 2021 2021 FY
Q1 2019 $14,187,771 +$952,170 +7.2% 30 Apr 2019 10-K 13 Aug 2019 2019 FY
Q1 2018 $13,235,601 +$1,714,306 +15% 30 Apr 2018 10-K 13 Aug 2019 2019 FY
Q1 2017 $11,521,295 +$1,266,869 +12% 30 Apr 2017 10-K 13 Aug 2019 2019 FY
Q1 2016 $10,254,426 -$2,871,911 -22% 30 Apr 2016 10-K 20 Jul 2018 2018 FY
Q1 2015 $13,126,337 +$305,243 +2.4% 30 Apr 2015 10-K 27 Jul 2017 2017 FY
Q1 2014 $12,821,094 +$364,071 +2.9% 30 Apr 2014 10-K 29 Jul 2016 2016 FY
Q1 2013 $12,457,023 +$256,694 +2.1% 30 Apr 2013 10-K 29 Jul 2016 2016 FY
Q1 2012 $12,200,329 30 Apr 2012 10-K/A 19 Jan 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.